BiotechTube

olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessary

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Isolated Systolic Hypertension

Conditions

Isolated Systolic Hypertension

Trial Timeline

Jul 1, 2003 → Feb 1, 2005

NCT ID
NCT00751829

About olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessary

olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessary is a phase 3 stage product being developed by Daiichi Sankyo for Isolated Systolic Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00751829. Target conditions include Isolated Systolic Hypertension.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00751829Phase 3Completed

Competing Products

4 competing products in Isolated Systolic Hypertension

See all competitors
ProductCompanyStageHype Score
Sprifermin (AS902330) 10 mcg + Sprifermin (AS902330) 30 mcg + Sprifermin (AS902330) 100 mcgMerckPhase 2
52
Rebif®MerckPhase 3
77
romiplostimAmgenPhase 2
51
6R-BH4BioMarin PharmaceuticalPhase 2
49

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85